Aptus Pharma bulk deals, insider trading and stake changes
BSE: 544529Pharmaceuticals & BiotechnologySmall Cap
Last close ₹491.50down ₹10.00 (1.99%)
Share price at the BSE close on 23 Oct 2026. Previous close ₹501.50.
52-week range of traded prices to 23 Oct 2026
₹48.10Low, 27 Oct 2025₹510.90High, 23 Oct 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹843 Cr2,265th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 21 Oct 2026
- 106.0
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 21 Oct 2026
- 29.7
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 21 Oct 2026
- 31.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026. The filing of 21 Oct 2026
- 0.43
- Volume, BSEVolume. Shares traded on the last trading day.
- 18,000
Promoter and insider buying and selling
Trades made since 23 Oct 2025.Aptus Pharma promoter holding
No promoter, director, key manager or employee bought or sold on the market.
- Promoters and promoter group: no market trade · 9 off-market moves
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Aptus Pharma insider trading
All 9 disclosures on record.Insider trading, all companies
May 2026
- BonusEvery 2 shares became 5 on 12 May 2026. The lines below are on the share count before it.
- Chatrabhujbhai Butani₹4.34 Cr1,24,000 sharesGave · Promoter Group · 11 May 2026 · disclosed 13 May · Inter-se-Transfer · stake 3.28% before, 1.47% after
- TEJASH MAHESHCHANDRA HATHI₹0.35 Cr10,000 sharesReceived · Promoter Group · 11 May 2026 · disclosed 13 May · Inter-se-Transfer · stake 11.30% before, 11.44% after
- Riddhish Natwarlal Tanna₹0.63 Cr18,000 sharesReceived · Promoter Group · 11 May 2026 · disclosed 13 May · Inter-se-Transfer · stake 8.38% before, 8.64% after
- Milly Chetan Lalseta₹0.63 Cr18,000 sharesReceived · Promoter Group · 11 May 2026 · disclosed 13 May · Inter-se-Transfer · stake 8.38% before, 8.64% after
- Kunjal Piyushbhai Unadkat₹0.63 Cr18,000 sharesReceived · Promoter Group · 11 May 2026 · disclosed 13 May · Inter-se-Transfer · stake 8.38% before, 8.64% after
- Kripaliben Mayank Thakker₹0.63 Cr18,000 sharesReceived · Promoter Group · 11 May 2026 · disclosed 13 May · Inter-se-Transfer · stake 8.38% before, 8.64% after
- KAPILBHAI HASMUKHBHAI CHANDARANA₹0.35 Cr10,000 sharesReceived · Promoter Group · 11 May 2026 · disclosed 13 May · Inter-se-Transfer · stake 11.30% before, 11.44% after
- Ghanshyam Vinubhai Pansuriya₹0.49 Cr14,000 sharesReceived · Promoter Group · 11 May 2026 · disclosed 13 May · Inter-se-Transfer · stake 5.10% before, 5.31% after
- Gaurang Rameshchandra Thakker₹0.63 Cr18,000 sharesReceived · Promoter Group · 11 May 2026 · disclosed 13 May · Inter-se-Transfer · stake 8.38% before, 8.64% after
Trades by the company's promoters, directors, key managers, employees and their relatives, as each disclosed them. Value is what the filer stated; the mode is shown where the shares moved off the market.
Aptus Pharma stake sales and purchases
All 9 disclosures on record.
May 2026
- BonusEvery 2 shares became 5 on 12 May 2026. The lines below are on the share count before it.
- AcquiredKripaliben Mayank Thakker · promoter0.26% of the company18,000 sharesholds 8.64% after11 May 2026 · filed under the 2% rule · Off Market / Inter se transfer
- AcquiredKunjal Unadkat · promoter0.26% of the company18,000 sharesholds 8.64% after11 May 2026 · filed under the 2% rule · Off Market / Inter se transfer
- AcquiredRiddhish Natwarlal Tanna · promoter0.26% of the company18,000 sharesholds 8.64% after11 May 2026 · filed under the 2% rule · Off Market / Inter se transfer
- AcquiredMilly Chetan Lalseta · promoter0.26% of the company18,000 sharesholds 8.64% after11 May 2026 · filed under the 2% rule · Off Market / Inter se transfer
- AcquiredGaurang Thakker · promoter0.26% of the company18,000 sharesholds 8.64% after11 May 2026 · filed under the 2% rule · Off Market / Inter se transfer
- SoldChatrabhuj Vallabhbhai Butani · promoter1.81% of the company1,24,000 sharesholds 1.47% after11 May 2026 · filed under the 2% rule · Off Market / Inter se transfer
- AcquiredTejash Hathi · promoter0.15% of the company10,000 sharesholds 11.44% after11 May 2026 · filed under the 2% rule · Off Market
- AcquiredGhanshyam Pansuriya · promoter0.20% of the company14,000 sharesholds 5.31% after11 May 2026 · filed under the 2% rule · Off Market / Inter se transfer
- AcquiredKapilbhai Chandarana · promoter0.15% of the company10,000 sharesholds 11.44% after11 May 2026 · filed under the 2% rule · Off Market
The 5% rule: an investor discloses on reaching 5% of the company. The 2% rule: a holder of 5% or more discloses each change of 2% or more, including one that takes it below 5%. A transfer exempt from an open offer, the offer to buy from every other shareholder that a large purchase otherwise brings, is disclosed too. Each line shows what its filing states, which can be a smaller change than its rule names.
Aptus Pharma bulk deals
Last 12 months, since 23 Oct 2025: 8 bulk deals, ₹1.22 Cr bought and ₹7.91 Cr sold Bought and sold in deals. Each deal's shares times its price, added up for the buyers and apart for the sellers, so a block deal, which names both, counts on each side.Today's bulk and block deals, all companies
ValueValue of a deal. The shares traded times the deal's price.Per cent of the companyPer cent of the company. The shares traded as a percentage of all the company's shares in issue on the day of the deal.
BonusEvery 2 shares became 5 on 12 May 2026. The lines below are on the share count before it.
Tuesday 30 Dec 20251 firm · ₹0 bought · ₹0.61 Cr soldNet sold ₹0.61 Cr
- SoldZEAL GLOBAL OPPORTUNITIES FUNDSold 38,000 at ₹161.500.55% of the company₹0.61 Cr
Friday 26 Dec 20251 firm · ₹0 bought · ₹1.54 Cr soldNet sold ₹1.54 Cr
- Sold31 DEGREES NORTH FUND ISold 96,000 at ₹160.001.40% of the company₹1.54 Cr
Monday 10 Nov 20251 firm · ₹0 bought · ₹0.61 Cr soldNet sold ₹0.61 Cr
- SoldZEAL GLOBAL OPPORTUNITIES FUNDSold 40,000 at ₹151.500.58% of the company₹0.61 Cr
Thursday 30 Oct 20252 firms · ₹0 bought · ₹2.24 Cr soldNet sold ₹2.24 Cr
- SoldSAUMIK KETANKUMAR DOSHISold 1,04,000 at ₹132.161.52% of the company₹1.37 Cr
- SoldPAULOMI KETANKUMAR DOSHISold 66,000 at ₹131.690.96% of the company₹0.87 Cr
Tuesday 28 Oct 20253 firms · ₹1.22 Cr bought · ₹2.13 Cr soldNet sold ₹0.91 Cr
- Sold31 DEGREES NORTH FUND ISold 96,000 at ₹127.551.40% of the company₹1.22 Cr
- BoughtPAULOMI KETANKUMAR DOSHIBought 96,000 at ₹127.551.40% of the company₹1.22 Cr
- SoldEMINENCE GLOBAL FUND PCC - EUBILIA CAPITAL PARTNERS FUND ISold 72,000 at ₹125.791.05% of the company₹0.91 Cr
Friday 24 Oct 20251 firm · ₹0 bought · ₹0.78 Cr soldNet sold ₹0.78 Cr
- SoldSAUMIK KETANKUMAR DOSHISold 60,000 at ₹130.000.87% of the company₹0.78 Cr
Tuesday 21 Oct 20252 firms · ₹0.61 Cr bought · ₹0.61 Cr soldNet nil
- BoughtJEET PARESH VAGHANIBought 50,000 at ₹122.000.73% of the company₹0.61 Cr
- SoldSAUMIK KETANKUMAR DOSHISold 50,000 at ₹122.000.73% of the company₹0.61 Cr
Friday 17 Oct 20251 firm · ₹0.43 Cr bought · ₹0.43 Cr soldNet nil
- Both waysRITIKBought 36,000 at ₹120.43Sold 36,000 at ₹120.330.52% of the companyNet nil₹0.43 Cr bought
Wednesday 1 Oct 20251 firm · ₹0 bought · ₹0.31 Cr soldNet sold ₹0.31 Cr
- SoldPURE BROKING PRIVATE LIMITEDSold 38,000 at ₹81.03₹0.31 Cr
Tuesday 30 Sep 20253 firms · ₹3.11 Cr bought · ₹0 soldNet bought ₹3.11 Cr
- BoughtSAUMIK KETANKUMAR DOSHIBought 2,94,000 at ₹82.79₹2.43 Cr
- BoughtVIVEKKAULBought 42,000 at ₹84.28₹0.35 Cr
- BoughtPURE BROKING PRIVATE LIMITEDBought 38,000 at ₹84.84₹0.32 Cr
A bulk deal is one client trading half a per cent or more of the shares in a day; a block deal is a large trade in the exchange's separate block window, its buyer and its seller each on a line of their own. A firm that bought and sold the shares the same day is on one line, with its net. All 15 deals on record since listing on 30 Sep 2025.